Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID‐19 pandemic
Open Access
- 12 January 2021
- journal article
- letter
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (5) , 1271-1273
Abstract
To assess the impact of COVID‐19 restrictions on cystic fibrosis (CF) pulmonary exacerbations (PEx) we performed a retrospective review of PEx events at our CF Center and compared the rate of PEx in 2019 versus 2020. Restrictions on social interaction due to the COVID‐19 pandemic were associated with a lower number of PEx events at our pediatric CF Center, suggesting that these restrictions also reduced exposure to other respiratory viral infection in children with CF.Keywords
Funding Information
- National Institutes of Health (T35HL110854)
- Cystic Fibrosis Foundation (SANDER18Y7)
This publication has 8 references indexed in Scilit:
- COVID-19 public health measures and respiratory syncytial virusThe Lancet Child & Adolescent Health, 2020
- Clinical impact of respiratory virus in pulmonary exacerbations of children with Cystic FibrosisPLOS ONE, 2020
- Decreased Influenza Activity During the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Disease Control, Civil Liberties, and Mass Testing — Calibrating Restrictions during the Covid-19 PandemicNew England Journal of Medicine, 2020
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic FibrosisJAMA, 2012
- The role of respiratory viruses in cystic fibrosisJournal of Cystic Fibrosis, 2008